Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Apo Plus Station Carries Out MBO
October 18, 2010
- NEW PRODUCTS
October 18, 2010
- Gov't to Create Fund to Subsidize Vaccination against HPV
October 18, 2010
- Sandoz Launches First Ramosetron Generic in Japan
October 18, 2010
- Takeda Ties Up with Envoy to Develop Schizophrenia Drugs
October 18, 2010
- Market for OTC Kampo Medicines to Grow 0.8% to ¥239.4 Bil. in 2010
October 18, 2010
- Ranbaxy Granted 180-Day Exclusivity for Generic Aricept in the US
October 18, 2010
- Asubio Pharma Starts Operation in Kobe
October 18, 2010
- 2-Week Prescription Limit Lifted for Reflex, Remeron
October 18, 2010
- 2 Japanese Scientists Awarded Nobel Prize in Chemistry
October 18, 2010
- BI Initiates PIII for BIBW 2992 for Advanced Breast Cancer
October 18, 2010
- KCI Aims at US$100 Mil. Sales with V.A.C. Therapy System in Japan
October 18, 2010
- Prof. Negishi's Distinction Marks Major Landmark in Teijin's History: President Ohyagi
October 18, 2010
- Kyowa Kirin Begins KW-0761 PIIb for T/NK-Cell Lymphoma
October 18, 2010
- Kyowa Kirin Licenses KW-6356 to Lundbeck
October 18, 2010
- Public-Knowledge Based Applications Recommended for 9 APIs, 10 Indications
October 18, 2010
- LTT Bio-Pharma Starts PI for Inhaled PC-SOD Formulation
October 18, 2010
- NBI, Astellas to Emphasize Long-Lasting Efficacy of Micamlo
October 18, 2010
- Gov't-Industry Dialogue Essential: New Health Minister Hosokawa
October 18, 2010
- Hisamitsu Discontinues Development of HKT-500 in the US
October 18, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…